Hali Miller
Psychiatric/Mental Health · Covington, LANPI 1700330396
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,600 of the $8,319 with a category attached, or 67.3%. Teva Pharmaceuticals USA, Inc. accounts for 89.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $7,308 and has fallen 95.2% since, to $348 in 2025. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $86.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$7K
- Neurocrine Biosciences, Inc.$246
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$169
- Lundbeck LLC$124
- Indivior Inc.$97
- Johnson & Johnson$80
- plus $179 from 5 others
What the payments were for
- Speaking & faculty fees$5,60067%
- Travel & lodging$81610%
- Food & beverage$1,75121%
- Education$1512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 47 | $7,424 |
| Neurocrine Biosciences, Inc. | 10 | $246 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $169 |
| Lundbeck LLC | 8 | $124 |
| Indivior Inc. | 6 | $97 |
| Johnson & Johnson | 5 | $80 |
| AbbVie | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Alkermes, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$6,442
- Austedo XR$122
How this compares
$8,319 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 28 | $95,359 |
| UzedyRisperidone | 21 | $70,101 |
| Abilify MaintenaAripiprazole | 18 | $42,670 |
| VraylarCariprazine Hcl | 27 | $38,235 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $29,091 |
| CaplytaLumateperone Tosylate | 16 | $24,953 |
| Atomoxetine Hcl | 39 | $6,347 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $2,216 |
| Oxcarbazepine | 45 | $1,527 |
| Fluoxetine Hcl | 89 | $1,329 |
| Mirtazapine | 65 | $1,300 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,295 |
| Gabapentin | 106 | $1,102 |
| Aripiprazole | 64 | $1,042 |
| Buspirone Hcl | 42 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $80 | $95,35928 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $7,424 | $70,10121 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $39 | $42,67018 claims |
| AbbVieVraylar | $76 | $38,23527 claims |
| Alkermes, Inc.Lybalvi | $38 | $29,09118 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $169 | $24,95316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Covington
- Debbie PierceCovington$7K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.